Novartis to acquire Avidity Biosciences for about $12 billion

Swiss drugmaker Novartis announced its acquisition of U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash, or $72 per share, representing a 46% premium. This strategic move aims to bolster Novartis's portfolio in rare muscle disorders, expand into areas with limited treatment options, and address impending patent expirations for key drugs like Entresto and Cosentyx. As part of the deal, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded entity, Spinco, while Novartis gains Avidity's clinical-stage pipeline of first-in-class RNA therapeutics for neuromuscular diseases, with candidates expected to seek approval by 2026. The acquisition also helps Novartis strengthen its U.S. market presence amidst potential pharmaceutical tariff threats.

Analysis

Novartis (NVS) has agreed to acquire U.S. biotech firm Avidity Biosciences (RNA) for $12 billion in cash, representing a substantial 46% premium over Avidity's Friday closing price at $72 per share. This strategic acquisition, valued significantly above Avidity's pre-announcement market cap of $6.7 billion, underscores Novartis's aggressive M&A strategy to bolster its pipeline. The deal is strongly positive for RNA shareholders, reflected in its 0.95 per-ticker sentiment.

The acquisition is primarily driven by Novartis's need to address impending patent expirations for blockbuster drugs like Entresto and Cosentyx, by expanding into the high-growth rare disease market. Avidity brings a clinical-stage pipeline of first-in-class RNA therapeutics for neuromuscular disorders, including lead candidate Del-zota for Duchenne muscular dystrophy, with three experimental drugs expected to seek approval by 2026. This move strengthens Novartis's presence in areas with limited treatment options and leverages innovative RNA technology.

A notable aspect of the transaction is the planned spin-off of Avidity's early-stage precision cardiology programs into a new publicly traded entity, Spinco, allowing Novartis to focus on the core neuromuscular assets. Furthermore, the acquisition helps Novartis establish a stronger U.S. market foothold, potentially mitigating risks associated with proposed pharmaceutical tariffs from the Trump administration, a factor also influencing other major pharma players like J&J and Sanofi. This reflects a broader industry response to evolving trade policies.

Key Decisions for Investors

• Novartis investors should assess the strategic value of this acquisition in mitigating patent cliff risks and expanding into high-growth rare disease therapeutics.
• Avidity Biosciences shareholders should prepare for the $72 per share cash acquisition and evaluate the future prospects of the spun-off Spinco entity.
• Broader pharmaceutical investors should observe how this deal reflects industry efforts to secure U.S. market presence amidst evolving trade policies and potential tariffs.